ArticleNature2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 133 citations in OpenAlex.
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.Archiv der Pharmazie · 2026Review
- Single cell spatial transcriptomics track the evolutionary hierarchy and microenvironment remodeling during breast carcinoma invasion.Nature communications · 2026Article
- Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model.Nature communications · 2026Article
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.Cell reports. Medicine · 2026Article
- mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway.Cell death & disease · 2026Article
- Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Nature communications · 2026Article
- Identification of cancer mini-drivers by deciphering selective landscape in the cancer genome.Briefings in bioinformatics · 2026Article
- A molecular glue halts RAS-MAPK signaling.Nature cancer · 2026Article
- The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers.Nature cancer · 2026Article
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor.bioRxiv : the preprint server for biology · 2025Article
- Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.Pigment cell & melanoma research · 2025Article
- Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.Research square · 2025Article
- Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.Molecular medicine (Cambridge, Mass.) · 2025Article
- Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.Chinese medical journal · 2025Review
- CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer.Cancer research · 2025Article
- Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.Nature chemical biology · 2025Article
- RAS signaling gets granular.Nature chemical biology · 2025Article
- Artificial intelligence and anti-cancer drugs' response.Acta pharmaceutica Sinica. B · 2025Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 9 institutions in 2 countries.
Ivana Yen *Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Frances Shanahan *Department of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Jeeyun Lee *Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0002-4911-6165
Yong Sang Hong *Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Sang Joon Shin *Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Amanda R MooreDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3864-6387
Jawahar SudhamsuDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0737-2299
Matthew T ChangDepartment of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
Inhwan BaeDepartment of New Chemical Entity Discovery, Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.ORCID http://orcid.org/0000-0001-5390-2401
Darlene Dela CruzDepartment of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
Thomas HunsakerDepartment of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
Christiaan KlijnDepartment of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
Nicholas P D LiauDepartment of Structural Biology, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3887-899X
Eva LinDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Scott E MartinDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Zora ModrusanDepartment of Microchemistry, Proteomics and Lipidomics, Genentech Inc., South San Francisco, CA, USA.
Robert PiskolDepartment of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8942-9943
Ehud SegalDepartment of Translational Oncology, Genentech Inc., South San Francisco, CA, USA.
Avinashnarayan VenkatanarayanDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Xin YeDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Jianping YinDepartment of Structural Biology, Genentech Inc., South San Francisco, CA, USA.
Liangxuan ZhangDepartment of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Jin-Soo KimDepartment of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.
Hyeong-Seok LimDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kyu-Pyo KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Yu Jung KimDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Hye Sook HanDepartment of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
Soo Jung LeeDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Kyungpook National University, Daegu, South Korea.
Seung Tae KimDivision of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Minkyu JungDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Yoon-Hee HongDepartment of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.ORCID http://orcid.org/0000-0002-8224-4396
Young Su NohDepartment of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.ORCID http://orcid.org/0000-0002-4204-2503
Munjeong ChoiDepartment of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
Oakpil HanDepartment of Clinical Research and Development, Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea.
Malgorzata NowickaDepartment of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Shrividhya SrinivasanDepartment of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Yibing YanDepartment of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
Tae Won KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. twkimmd@amc.seoul.kr.ORCID http://orcid.org/0000-0001-9522-1997
Shiva MalekDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA. shivam@gene.com.ORCID http://orcid.org/0000-0002-9526-7968
Ulsan College · KRHanmi Pharmaceutical (South Korea) · KRSamsung Medical Center · KRYonsei University · KRChungbuk National University Hospital · KRGene Therapy Laboratory · FRKyungpook National University Hospital · KRSeoul National University · KRSeoul National University Bundang Hospital · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAF
Indexed as
MutationAnimalsCell LineCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMelanomaMiceProtein MultimerizationProto-Oncogene Proteins A-rafraf KinasesProto-Oncogene Proteins A-rafraf Kinases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.